Inovio Pharmaceuticals, Inc.
INO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $218 | $832 | $10,262 | $1,775 |
| % Growth | -73.8% | -91.9% | 478.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $218 | $832 | $10,262 | $1,775 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $75,620 | $86,677 | $187,651 | $249,240 |
| G&A Expenses | $36,996 | $47,582 | $90,185 | $53,752 |
| SG&A Expenses | $36,996 | $47,582 | $90,185 | $53,752 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $10,513 | $0 | $0 |
| Operating Expenses | $112,617 | $144,772 | $277,836 | $302,993 |
| Operating Income | -$112,399 | -$143,940 | -$267,574 | -$301,218 |
| % Margin | -51,616.9% | -17,300.3% | -2,607.4% | -16,972.3% |
| Other Income/Exp. Net | $5,145 | $8,823 | -$12,245 | -$2,441 |
| Pre-Tax Income | -$107,254 | -$135,117 | -$279,818 | -$303,659 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$107,254 | -$135,117 | -$279,818 | -$303,659 |
| % Margin | -49,254.3% | -16,239.9% | -2,726.7% | -17,109.9% |
| EPS | -3.95 | -6.09 | -14.07 | -1.42 |
| % Growth | 35.1% | 56.7% | -890.8% | – |
| EPS Diluted | -3.95 | -6.09 | -14.07 | -1.42 |
| Weighted Avg Shares Out | 27,161 | 22,174 | 19,885 | 214,623 |
| Weighted Avg Shares Out Dil | 27,161 | 22,174 | 19,885 | 214,623 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,767 | $8,133 | $4,782 | $3,363 |
| Interest Expense | $178 | $1,223 | $1,254 | $1,936 |
| Depreciation & Amortization | $3,130 | $3,504 | $5,496 | $4,731 |
| EBITDA | -$103,946 | -$130,391 | -$270,903 | -$296,557 |
| % Margin | -47,735.2% | -15,671.8% | -2,639.8% | -16,709.7% |